Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
Crossref DOI link: https://doi.org/10.1007/s12325-020-01418-7
Published Online: 2020-07-09
Published Print: 2020-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rui, Mingjun
Shi, Fenghao
Shang, Ye
Meng, Rui
Li, Hongchao
Text and Data Mining valid from 2020-07-09
Version of Record valid from 2020-07-09
Article History
Received: 25 May 2020
First Online: 9 July 2020